Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 5/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29905943 | 0.83 | KCNN4 (0.55) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL31578414 | 0.79 | KCNN4 (0.50) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL1072785 | 0.79 | KCNN4 (0.50) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL9518989 | 0.77 | KIF11 (0.40) | KCNN4TSHRALDH1A1CYP1A2CYP2D6 | |
| SCHEMBL2898192 | 0.75 | KCNN4 (0.46) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL8854227 | 0.75 | KCNN4 (0.46) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL28535968 | 0.75 | KCNN4 (0.46) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL6882699 | 0.75 | TSHR (0.46) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL1064377 | 0.75 | TSHR (0.43) | KCNN4HTTTSHRALDH1A1CYP1A2 | |
| SCHEMBL6379504 | 0.74 | KCNN4 (0.50) | KCNN4TSHRALDH1A1CYP1A2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 158 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114959712-A | Vapor phase corrosion inhibitor and preparation method thereof | 中国石油化工股份有限公司 | 2022-08-30 | — | — | CN | claimed |
| US-20060216338-A1 | Composition and method of treatment for heel pain | EASTERLING W J | 2006-09-28 | — | — | US | claimed |
| US-20050020569-A1 | Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis | EASTERLING W JERRY (US) | 2005-01-27 | — | — | US | claimed |
| US-20040253300-A1 | Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers | EASTERLING W JERRY (US) | 2004-12-16 | — | — | US | claimed |
| US-20040170674-A1 | For the topical application of one or more calcium channel blocker agents suspended in one or more carriers with penetration enhancing agent's two effect transdermal delivery of the calcium channel blocker agent | EASTERLING W JERRY (US) | 2004-09-02 | — | — | US | claimed |
| US-20040170675-A1 | Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method | EASTERLING W JERRY (US) | 2004-09-02 | — | — | US | claimed |
| WO-2003034999-A2 | MEDICATION AND METHOD FOR REMEDIATING EXISTING SCARS THROUGH TRANSDERMAL TOPICAL DELIVERY OF CALCIUM CHANNEL BLOCKERS | EASTERLING JERRY W (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2003034998-A2 | COMPOSITION AND METHOD FOR TREATING ERECTILE DYSFUNCTION AND REDUCING FIBROSIS IN ERECTILE TISSUE OF THE HUMAN PENIS | EASTERLING JERRY W (US) | 2003-05-01 | — | — | WO | claimed |
| WO-2002085344-A1 | NONINVASIVE METHODS FOR TREATING HEMANGIOMAS | EASTERLING W JERRY (US) | 2002-10-31 | — | — | WO | claimed |
| US-20020160995-A1 | Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers | EASTERLING W JERRY (US) | 2002-10-31 | — | — | US | claimed |
| US-20020151537-A1 | Composition and method for treating erectile dysfunction and reducing fibrosis in erectile tissue of the human penis | EASTERLING W JERRY (US) | 2002-10-17 | — | — | US | claimed |
| EP-1105113-A4 | COMPOSITION AND METHOD FOR TREATING PEYRONIE'S DISEASE AND OTHER SUB-DERMAL PLAQUE MANIFESTATION DISORDERS | EASTERLING JERRY W (US) | 2002-08-21 | — | — | EP | claimed |
| US-20020028234-A1 | Noninvasive method for treating hemangiomas through transdermal delivery of calcium channel blocker agents and medicament for use in such method | FIBRO-GEN, LTD. | 2002-03-07 | — | — | US | claimed |
| US-20020022664-A1 | Method for treating aberrant fibrotic tissue manifestations with topical calcium channel blocker preparations and improved composition for such treatment and improved method for the manufacture thereof | EASTERLING W JERRY (US) | 2002-02-21 | — | — | US | claimed |
| US-20020019445-A1 | Noninvasive method for treating cellulite through transdermal delivery of calcium channel blocker agents and medicament for use in such method | EASTERLING W JERRY (US) | 2002-02-14 | — | — | US | claimed |
| US-20010047037-A1 | METHOD FOR NON-INVASIVE TOPICAL TREATMENT OF PEYRONIE'S DISEASE, DUPUYTREN'S HAND CONTRACTURE AND LEDEDERHOSE FIBROISIS | FIBRO-GEN, LTD. | 2001-11-29 | — | — | US | claimed |
| EP-1105113-A1 | COMPOSITION AND METHOD FOR TREATING PEYRONIE'S DISEASE AND OTHER SUB-DERMAL PLAQUE MANIFESTATION DISORDERS | Easterling, Jerry W. (US) | 2001-06-13 | — | — | EP | claimed |
| WO-2000007587-A9 | COMPOSITION AND METHOD FOR TREATING PEYRONIE'S DISEASE AND OTHER SUB-DERMAL PLAQUE MANIFESTATION DISORDERS | EASTERLING W JERRY (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000007587-A1 | COMPOSITION AND METHOD FOR TREATING PEYRONIE'S DISEASE AND OTHER SUB-DERMAL PLAQUE MANIFESTATION DISORDERS | EASTERLING W JERRY (US) | 2000-02-17 | — | — | WO | claimed |
| US-4690935-A | Inhibition of tumor growth and metastasis with calcium channel blocker compounds | WAYNE STATE UNIVERSITY (US) | 1987-09-01 | — | — | US | claimed |